- 1 Summary
- 2 FAQ
- 2.1 1. What is para-chloromethamphetamine (4-CMA)?
- 2.2 2. What are the effects of 4-CMA on serotonin levels?
- 2.3 3. Are there any long-term effects associated with 4-CMA use?
- 2.4 4. How does 4-CMA compare to methamphetamine regarding inducing conditioned taste aversion?
- 2.5 5. What distinguishes 4-CMA from amphetamine and methamphetamine compounds?
- 2.6 6. Where was 4-CMA first identified outside of laboratory settings?
- 2.7 7. Is 4-CMA a legal substance?
- 3 References
Para-chloromethamphetamine, also called 4-chloromethamphetamine and 4-CMA, is a stimulant that serves as the N-methyl derivative and prodrug of the neurotoxic compound para-chloroamphetamine (4-CA). This substance has been observed to decrease serotonin levels in rats. Further exploration into the enduring effects of chloroamphetamines revealed that the administration of 4-CMA led to a prolonged reduction in serotonin levels and the activity of tryptophan hydroxylase in the brain one month after a single dose of the drug was administered.
In studies involving rats, it was found that 4-chloromethamphetamine was more effective at inducing conditioned taste aversion compared to methamphetamine.
During the 1960s, 4-chloromethamphetamine was subject to further investigation alongside 4-CA. It was noted that these compounds differed from their parent amphetamine and methamphetamine substances, as they exhibited only a mild central stimulant effect in both animals and humans. Interestingly, they seemed to act more like antidepressants rather than typical stimulants.
It is noteworthy that 4-chloromethamphetamine was identified outside of laboratory settings for the first time at the Tomorrowland festival edition in 2015 when a tablet containing the substance was found in the possession of a drug dealer (see picture).
|CompTox Dashboard (EPA)||DTXSID00897230|
|Chemical and physical data|
|Molar mass||183.68 g·mol−1|
1. What is para-chloromethamphetamine (4-CMA)?
Para-chloromethamphetamine, also known as 4-CMA, is a stimulant drug that acts as the N-methyl derivative and prodrug of another neurotoxic drug called para-chloroamphetamine (4-CA).
2. What are the effects of 4-CMA on serotonin levels?
4-CMA has been found to decrease serotonin levels in laboratory studies involving rats. This effect can have implications for mood and neurotransmitter function.
3. Are there any long-term effects associated with 4-CMA use?
Research has shown that the administration of 4-CMA can lead to a prolonged reduction in serotonin levels and the activity of tryptophan hydroxylase in the brain, even one month after a single drug dose is administered.
4. How does 4-CMA compare to methamphetamine regarding inducing conditioned taste aversion?
Studies on rats have indicated that 4-chloromethamphetamine is more potent inducing conditioned taste aversion than methamphetamine. This suggests that it may have distinct effects on behavior and aversion.
5. What distinguishes 4-CMA from amphetamine and methamphetamine compounds?
In investigations during the 1960s, 4-chloromethamphetamine was noted for its differences from amphetamine and methamphetamine substances. It exhibited only a mild central stimulant effect in both animals and humans and appeared to act more like an antidepressant rather than a typical stimulant.
6. Where was 4-CMA first identified outside of laboratory settings?
4-Chloromethamphetamine was discovered outside of laboratory settings for the first time at the Tomorrowland festival edition in 2015 when a tablet containing the substance was found in the possession of a drug dealer.
7. Is 4-CMA a legal substance?
The legal status of 4-CMA may vary by country and region. Knowing local regulations and laws regarding its possession and use is essential. Always prioritize safety and legal compliance when dealing with such substances.
- Johnson MP, Conarty PF, Nichols DE (July 1991). “Neurochemical Properties of MDMA Analogues”. European Journal of Pharmacology. 200 (1): 9–16. doi:10.1016/0014-2999(91)90659-E. PMID 1685125.
- Fuller RW, Baker JC, Perry KW, Molloy BB (October 1975). “Comparing the Effects of Amphetamine Derivatives in Rats”. Neuropharmacology. 14 (10): 739–746. doi:10.1016/0028-3908(75)90099-4. PMID 1196472. S2CID 9620299.
- Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE (April 2012). “Amphetamine Derivatives and Their Effects on Behavior and Neurochemistry in Mice”. Psychopharmacology. 220 (3): 495–508. doi:10.1007/s00213-011-2504-0. PMC 3289749. PMID 21993877.
- Pletscher A, Burkard WP, Bruderer H, Gey KF (November 1963). “Reducing Cerebral 5-Hydroxytryptamine Levels with an Arylalkylamine”. Life Sciences. 2 (11): 828–833. doi:10.1016/0024-3205(63)90094-8. PMID 14078137.
- Fuller RW, Hines CW, Mills J (April 1965). “Lowering Brain Serotonin Levels with Chloramphetamines”. Biochemical Pharmacology. 14 (4): 483–488. doi:10.1016/0006-2952(65)90221-2. PMID 14322972.
- Sanders-Bush E, Bushing JA, Sulser F (January 1975). “Long-term Effects of Amphetamine Derivatives on Serotonergic Mechanisms”. The Journal of Pharmacology and Experimental Therapeutics. 192 (1): 33–41. PMID 1123726.
- Booth DA, Pilcher CW, D’Mello GD, Stolerman IP (December 1977). “Comparative Potencies of Stimulants in Taste Aversion Experiments”. British Journal of Pharmacology. 61 (4): 669–677. doi:10.1111/j.1476-5381.1977.tb07560.x. PMC 1668069. PMID 597669.
- van Praag HM, Korf J, van Woudenberg F, Kits TP (July 1968). “Influencing Indoleamine Metabolism with an Antidepressant Amphetamine Derivative”. Psychopharmacologia. 13 (2): 145–160. doi:10.1007/BF00404812. PMID 5678577. S2CID 30028917.
- Kits TP, van Praag HM (1970). “Antidepressant Effects of p-Chloro-N-Methylamphetamine”. Acta Psychiatrica Scandinavica. 46 (4): 365–373. doi:10.1111/j.1600-0447.1970.tb02126.x. PMID 5502782. S2CID 2211532.
- van Praag HM, Korf J, van Woudenberg F (December 1970). “Influence of Chlorinated Amphetamine Derivatives on Serotonin Synthesis in Humans”. Psychopharmacologia. 18 (4): 412–420. doi:10.1007/BF00402767. PMID 4923523. S2CID 27509683.
- van Praag HM, Schut T, Bosma E, van den Bergh R (March 1971). “Therapeutic Effects of Chlorinated Amphetamine Derivatives in Depressive Patients”. Psychopharmacologia. 20 (1): 66–76. doi:10.1007/BF00404060. PMID 5565748.
- Blanckaert P, Vanquekelberghe S, Coopman V, Risseeuw MD, Van Calenbergh S, Cordonnier J (July 2018). “Identification of 4-Chloromethamphetamine (4-CMA) in Seized Ecstasy and Its Impact on Public Health”. Forensic Science International. 288: 173–180. doi:10.1016/j.forsciint.2018.04.023. hdl:1854/LU-8569680. PMID 29753935. S2CID 21720366.